Deliver Your News to the World

First Successful HIFU Procedures for Human Kidney Cancer


FARMINGDALE, N.Y. - Misonix, Inc. (Nasdaq: MSON), a developer of ultrasonic medical device technology for the treatment of cancer and other chronic health conditions, has announced the results from its first human kidney cancer treatments using the Sonatherm 600 (“Sonatherm”), a medical device using high intensity focused ultrasound (“HIFU”). According to Dr. Michael A. Marberger, Chairman and Professor of the Department of Urology, University of Vienna Medical School, Vienna, Austria, where the treatments were performed, procedures were successfully completed with positive ablation effect noted on cancer cells in tumors within human kidneys.

The trial patients treated by Dr. Marberger’s team at University of Vienna Medical School were diagnosed to have cancerous kidney tumors and were candidates for full or partial nephrectomies (surgical removal of kidney). Each patient agreed to first have the kidney cancer treated laparoscopically with HIFU from the Sonatherm with the kidney still in place and before a nephrectomy was performed. After the cancerous areas of the kidney were removed through the traditional, surgical methods the HIFU treated areas were tested outside of the patient’s body. The results showed positive ablation of cancerous tissue treated by the Sonatherm.

“The Sonatherm 600 is an important new development for minimally invasive treatment of kidney cancer,” said Dr. Mark Sullivan, Senior Laparoscopic Surgeon and Honorary Lecturer at Oxford University Hospital. “The ability of this device to laparoscopically treat cancerous cells in the kidney effectively and safely has the potential to eliminate the need for nephrectomies, which may jeopardize patients’ health and are costly.”

“Using the Sonatherm’s HIFU technology to treat the cancer while keeping the kidney in place is a breakthrough process,” noted Dr. Marberger. “The process is unique and our preliminary results to date in using the device are very exciting.”

“We are thrilled by the Sonatherm HIFU clinical results detailed by Dr. Marberger and the extraordinary “buzz” being generated by all of our new medical technologies for the minimally and non-invasive treatment of cancer,” said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. “I am pleased to have been surrounded by such an impressive group of doctors from highly respected medical centers at the first international Laparoscopic Kidney HIFU study group meeting. There is clearly a high level of excitement by the progress we have made to date and the potential for the breakthrough technology for minimally invasive treatment which is only being done in the HIFU area by Misonix. With an entire day of EAU 2007 devoted to minimally invasive technologies and the participation of hundreds of surgeons from countries throughout Europe and around the world, it is clear that Misonix’s research and product development pursuits using HIFU technology are of significance to the global healthcare community. We believe Misonix possesses the most advanced HIFU platform of minimally invasive medical devices for the treatment of cancer. While a cure for cancer remains illusive, Misonix continues to make considerable advances in the development of unique products for effective and patient-friendly eradication of cancerous tissue.”


This news content was configured by WebWire editorial staff. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.